Age-related risk factors associated with primary contralateral breast cancer among younger women versus older women.

Abstract:

PURPOSE:Contralateral prophylactic mastectomy is increasing, despite unclear evidence of improving survival. To investigate the age-related risk factors for contralateral breast cancer (CBC). METHODS:This study included 8716 patients diagnosed with non-metastatic unilateral invasive breast cancer between 1989 and 2008. Data on primary tumor size, node metastasis, grade and subtype using individual matching were used to adjust for differences in the primary tumor and treatment between younger and older age groups. CBC risk factors, CBC-free survival, and annual CBC risk were analyzed by age. RESULTS:The younger group included 652 patients aged under 35 years, and the older group included 2608 women aged 35 years or older. The median time to CBC development was 6.1 years. CBC was detected in 6.6% of the women in the younger group and 2.5% of those in the older group. Multivariable analysis revealed a relative CBC risk of 2.48 in younger women compared to older women. The risk was significantly higher among women with human epidermal growth factor receptor 2 (HER2)-overexpressing tumors (hazard ratio [HR] 4.98), a family history of breast cancer (HR 7.79), and anti-hormone therapy (HR 3.46). In younger women with HER2-positive cancer, CBC occurrence peaked at 4.6 years after surgery, in those with hormone receptor-positive cancer, it peaked at 7.1 years after surgery, and in triple-negative disease cases, and it increased steadily over time. CONCLUSIONS:After adjusting for primary breast tumor characteristics, patients < 35 years old had 2.5 times the risk of CBC development compared to the older women. CBC occurrence peaked within 5 years after primary breast cancer in younger women with the HER2-positive subtype and after 5 years in cases with the hormone receptor-positive subtype.

authors

Yoon TI,Kwak BS,Yi OV,Kim S,Um E,Yun KW,Shin HN,Lee S,Sohn G,Chung IY,Kim J,Ko BS,Lee JW,Son BH,Ahn SH,Kim HJ

doi

10.1007/s10549-018-5031-4

subject

Has Abstract

pub_date

2019-02-01 00:00:00

pages

657-665

issue

3

eissn

0167-6806

issn

1573-7217

pii

10.1007/s10549-018-5031-4

journal_volume

173

pub_type

杂志文章
  • Intra-operative ultrasound versus wire-guided localization in the surgical management of non-palpable breast cancers: systematic review and meta-analysis.

    abstract:INTRODUCTION:The current standard of treatment for non-palpable breast cancers is wire-guided localization (WGL). WGL has its drawbacks and alternatives such as radio-guided surgery (RGL) and intra-operative ultrasound (IOUS) have been developed. The clinical effectiveness of all forms of RGL has been assessed against ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,meta分析,评审

    doi:10.1007/s10549-013-2639-2

    authors: Ahmed M,Douek M

    更新日期:2013-08-01 00:00:00

  • Obesity and subcutaneous fat patterning in relation to survival of postmenopausal breast cancer patients participating in the DOM-project.

    abstract::The effect of obesity and fat distribution on survival of breast cancer patients was studied prospectively in 241 women with a natural menopause who participated in a breast cancer screening project, the DOM-project in Utrecht, The Netherlands. Mean follow-up time was 9.1 years and endpoint of interest was death from ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/BF00665785

    authors: den Tonkelaar I,de Waard F,Seidell JC,Fracheboud J

    更新日期:1995-05-01 00:00:00

  • Strategies for the development of recombinant vaccines for the immunotherapy of breast cancer.

    abstract::The development of recombinant vaccines for specific immunotherapy of carcinoma represents a novel approach for the treatment of breast cancer and other tumor types. This article reviews the various parameters that should be considered in the development of recombinant vaccines. Several breast cancer associated antige...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,评审

    doi:10.1007/BF01803781

    authors: Schlom J,Kantor J,Abrams S,Tsang KY,Panicali D,Hamilton JM

    更新日期:1996-01-01 00:00:00

  • Quality control for estrogen receptor quantification by dextran-coated charcoal assay: a single laboratory's experience.

    abstract::Wide fluctuations in results obtained by different laboratories for the content of estrogen receptors from a single source of tissue powder were reported by several investigators at the 1979 NCI Consensus Committee Meeting for Steroid Receptors in Breast Cancer and were further supported by data collected by our labor...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/BF01805724

    authors: Raam S,Gelman R,Faulkner J,White GM,Cohen JL

    更新日期:1982-01-01 00:00:00

  • Staging of breast cancer: new recommended standard procedure.

    abstract:BACKGROUND:Staging procedures used to detect metastatic breast cancer at the time of diagnosis are bone scan (BS), chest X-ray (CXR), liver ultrasonography (LUS) and laboratory parameters (LP). These procedures are expensive and not all patients need them. We aimed to identify groups of patients with different risks fo...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1023/a:1014900600815

    authors: Ravaioli A,Pasini G,Polselli A,Papi M,Tassinari D,Arcangeli V,Milandri C,Amadori D,Bravi M,Rossi D,Fattori PP,Pasquini E,Panzini I

    更新日期:2002-03-01 00:00:00

  • Factors associated with long-term adherence to annual surveillance mammography among breast cancer survivors.

    abstract::Clinical practice guidelines recommend yearly surveillance mammography for breast cancer survivors, yet many women do not receive this service. The objective of this study was to evaluate factors related to long-term surveillance mammography adherence among breast cancer survivors. We conducted a retrospective cohort ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-013-2816-3

    authors: Wirtz HS,Boudreau DM,Gralow JR,Barlow WE,Gray S,Bowles EJ,Buist DS

    更新日期:2014-02-01 00:00:00

  • The association between HSD17B1 Ser312Gly polymorphism and breast cancer risk: a meta-analysis including 31,053 subjects.

    abstract::There are increasing evidences that HSD17B1 plays a significant role in the development of breast cancer. However, published data on the association between HSD17B1 Ser312Gly polymorphism and breast cancer risk are inconclusive. In order to derive a more precise estimation of this relationship, a meta-analysis includi...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,meta分析

    doi:10.1007/s10549-010-0784-4

    authors: Yao L,Cao LH,Qiu LX,Yu L

    更新日期:2010-09-01 00:00:00

  • HER-2/neu expression in primary and metastatic breast cancer.

    abstract::Introduction Trastuzumab is a highly effective therapy for the treatment of HER-2/neu positive breast cancer. To maximize benefit and minimize unnecessary toxicity, patient selection is essential. Currently HER-2/neu analysis is routinely performed only for primary invasive breast cancers, and trastuzumab therapy is r...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-008-9931-6

    authors: Lower EE,Glass E,Blau R,Harman S

    更新日期:2009-01-01 00:00:00

  • Adherence to adjuvant hormone therapy in low-income women with breast cancer: the role of provider-patient communication.

    abstract::To assess the impact of patient-provider communication on adherence to tamoxifen (TAM) and aromatase inhibitors (AIs) 36 months after breast cancer (BC) diagnosis in a low-income population of women. California statewide surveys were conducted among 921 low-income women with BC at 6, 18, and 36 months after BC diagnos...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-012-2387-8

    authors: Liu Y,Malin JL,Diamant AL,Thind A,Maly RC

    更新日期:2013-02-01 00:00:00

  • The value of embedding: integrated palliative care for patients with metastatic breast cancer.

    abstract:PURPOSE:The American Society of Clinical Oncology recommends concurrent palliative care (PC) for patients with metastatic cancer. Recent data show benefits of early PC (at least 90 days before death). However, little is known about PC among patients who die from metastatic breast cancer. METHODS:Patients with metastat...

    journal_title:Breast cancer research and treatment

    pub_type: 临床试验,杂志文章

    doi:10.1007/s10549-017-4556-2

    authors: Rabow M,Small R,Jow A,Majure M,Chien A,Melisko M,Belkora J,Esserman LJ,Rugo H

    更新日期:2018-02-01 00:00:00

  • Knowledge and perceptions of familial and genetic risks for breast cancer risk in adolescent girls.

    abstract::Evidence suggests early events might modify adult breast cancer risk and many adolescents learn of familial and genetic risks for breast cancer. Little is known about how adolescent girls understand and respond to breast cancer risk. Semi-structured interviews with 11-19 year-old girls at high-risk and population-risk...

    journal_title:Breast cancer research and treatment

    pub_type: 临床试验,杂志文章

    doi:10.1007/s10549-012-2254-7

    authors: Bradbury AR,Patrick-Miller L,Egleston BL,Schwartz LA,Sands CB,Shorter R,Moore CW,Tuchman L,Rauch P,Malhotra S,Rowan B,Van Decker S,Schmidheiser H,Bealin L,Sicilia P,Daly MB

    更新日期:2012-12-01 00:00:00

  • Liarozole fumarate (R85246): a novel imidazole in the treatment of receptor positive postmenopausal metastatic breast cancer.

    abstract::This phase II study of liarozole fumarate (R85246, liarozole), a novel imidazole with retinomimetic and aromatase inhibitory effects, was designed to determine the efficacy and tolerability in postmenopausal women with advanced breast cancer in progression, to correlate these effects with hormonal levels, and to evalu...

    journal_title:Breast cancer research and treatment

    pub_type: 临床试验,杂志文章

    doi:10.1023/a:1006320122711

    authors: Goss PE,Oza A,Goel R,Nabholtz JM,De Coster R,Bruynseels J,Reid C,Wadden N,Crump M,Tye LM

    更新日期:2000-01-01 00:00:00

  • Can diffusion-weighted MR imaging and contrast-enhanced MR imaging precisely evaluate and predict pathological response to neoadjuvant chemotherapy in patients with breast cancer?

    abstract::Clinical evidence regarding the value of MRI for therapy responses assessment in breast cancer is increasing. The objective of this study is to compare the diagnostic capability of diffusion-weighted MR imaging (DW-MRI) and contrast-enhanced MR imaging (CE-MRI) to evaluate and predict pathological response in breast c...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,meta分析,评审

    doi:10.1007/s10549-012-2033-5

    authors: Wu LM,Hu JN,Gu HY,Hua J,Chen J,Xu JR

    更新日期:2012-08-01 00:00:00

  • Analysis of the breast cancer methylome using formalin-fixed paraffin-embedded tumour.

    abstract:PURPOSE:Aberrant DNA methylation occurs frequently in breast carcinogenesis. Tools for translational epigenetic studies of breast cancer involving formalin-fixed paraffin-embedded (FFPE) human tissues have now been developed. Few studies have measured genome-wide methylation in DNA derived from paraffin-embedded tumour...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-016-3971-0

    authors: Wong EM,Joo JE,McLean CA,Baglietto L,English DR,Severi G,Wu HC,Terry MB,Hopper JL,Milne RL,Giles GG,Southey MC

    更新日期:2016-11-01 00:00:00

  • A real-world study of cardiac events in > 3700 patients with HER2-positive early breast cancer treated with trastuzumab: final analysis of the OHERA study.

    abstract:PURPOSE:Cardiac dysfunction risk associated with intravenous trastuzumab (H IV) treatment may differ in real-world practice versus randomized trials. We investigated cardiac events in patients with HER2-positive early breast cancer (EBC) treated with H IV as adjuvant therapy in routine practice. METHODS:The observatio...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-018-5058-6

    authors: Lidbrink E,Chmielowska E,Otremba B,Bouhlel A,Lauer S,Liste Hermoso M,Nüesch E,Shing M,Misra V

    更新日期:2019-02-01 00:00:00

  • Progesterone receptor variants found in breast cells repress transcription by wild-type receptors.

    abstract::Progesterone, through its nuclear receptors (PR), regulates the development and growth of breast cancers. PR also serve as markers of hormone dependence and prognosis in patients with this disease, and functional PR are required to mediate the antiproliferative effects of progestin therapies. We find that normal and m...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1023/a:1005941117247

    authors: Richer JK,Lange CA,Wierman AM,Brooks KM,Tung L,Takimoto GS,Horwitz KB

    更新日期:1998-04-01 00:00:00

  • Detection of LOH and mitochondrial DNA alterations in ductal lavage and nipple aspirate fluids from hngh-risk patients.

    abstract::We describe a method for the isolation of free DNA from ductal lavage (DL) and nipple aspirate fluid (NAF), and its evaluation for the presence of LOH at the BRCA1 and FHIT genes and for mitochondrial DNA (mtDNA) mutations at the D310 marker, to improve early detection of breast cancer. We evaluated 26 DL and six NAF ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1023/B:BREA.0000018406.03679.2e

    authors: Isaacs C,Cavalli LR,Cohen Y,Pennanen M,Shankar LK,Freedman M,Singh B,Liu M,Gallagher A,Rone JD,Dickson RB,Sidransky D,Haddad BR

    更新日期:2004-03-01 00:00:00

  • Inflammatory breast cancer (IBC): clues for targeted therapies.

    abstract::Inflammatory breast cancer (IBC) is the most aggressive type of advanced breast cancer characterized by rapid proliferation, early metastatic development and poor prognosis. Since there are few preclinical models of IBC, there is a general lack of understanding of the complexity of the disease. Recently, we have devel...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-013-2600-4

    authors: Fernandez SV,Robertson FM,Pei J,Aburto-Chumpitaz L,Mu Z,Chu K,Alpaugh RK,Huang Y,Cao Y,Ye Z,Cai KQ,Boley KM,Klein-Szanto AJ,Devarajan K,Addya S,Cristofanilli M

    更新日期:2013-07-01 00:00:00

  • Survival analysis of censored data: neural network analysis detection of complex interactions between variables.

    abstract::Neural networks can be used as pattern recognition systems in complex data sets. We are exploring their utility in performing survival analysis to predict time to relapse or death. This technique has the potential to find easily some types of very complex interactions in data that would not be easily recognized by con...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/BF00666212

    authors: De Laurentiis M,Ravdin PM

    更新日期:1994-01-01 00:00:00

  • Weight changes after adjuvant treatment in Korean women with early breast cancer.

    abstract:BACKGROUND:Weight gain is a common problem in breast cancer patients and is reported to be associated with poorer survival. However, most data are limited to Western women. We evaluated weight changes after adjuvant treatment in Korean women with early breast cancer. METHODS:The authors reviewed the records of 260 pat...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-008-9984-6

    authors: Han HS,Lee KW,Kim JH,Kim SW,Kim IA,Oh DY,Im SA,Bang SM,Lee JS

    更新日期:2009-03-01 00:00:00

  • The relationship of urinary and plasma androgens to steroid receptors and menopausal status in breast cancer patients and their influence on survival.

    abstract::The relationships between urinary 11-desoxy-17-oxo steroids (11-DOS), the ratio of 11-DOS to urinary 17-hydroxycorticosteroids (urinary discriminant ratio), plasma levels of the adrenal androgens dehydroepiandrosterone (DHA), DHA sulphate (DHAS), and 7 alpha-hydroxy DHA (7 alpha DHA), and tumour oestrogen receptor (ER...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/BF00665771

    authors: Mason BH,Holdaway IM,Skinner SJ,Kay RG

    更新日期:1994-01-01 00:00:00

  • Carotenoids and breast cancer risk: a meta-analysis and meta-regression.

    abstract::The purpose of this article is to comprehensively summarize the associations between carotenoids and breast cancer and quantitatively estimate their dose-response relationships. We searched PubMed, Embase, and Cochrane databases (from January 1982 to 1 May 2011) and the references of the relevant articles in English w...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,meta分析

    doi:10.1007/s10549-011-1723-8

    authors: Hu F,Wang Yi B,Zhang W,Liang J,Lin C,Li D,Wang F,Pang D,Zhao Y

    更新日期:2012-01-01 00:00:00

  • Design of preparative regimens for stem cell transplantation in breast cancer.

    abstract::We have evaluated tandem cycles of a tri-drug combination, termed CVP (cyclophosphamide, etoposide [VP-16], and cisplatin [Platinol]), at four levels in more than 300 patients with various types of tumors. Tandem CVP appears to be at least therapeutically equivalent to alternatives. A second potentially non-cross-resi...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,评审

    doi:10.1007/BF00668354

    authors: Spitzer G,Adkins D,Dunphy F,Petruska P,Spencer V,Velasquez W

    更新日期:1993-01-01 00:00:00

  • Peripheral T cell responses to tumour antigens are associated with molecular, immunogenetic and cellular features of breast cancer patients.

    abstract:PURPOSE:Breast cancer is a leading cause of cancer deaths in women, but despite steady improvements in therapies, treatment is still suboptimal. Immunotherapy holds promise as a more effective therapy for breast cancer; supporting this, our prior study showed that patients possessing HER2-reactive CD8+ T cells in blood...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-016-4037-z

    authors: Janssen N,Fortis SP,Speigl L,Haritos C,Sotiriadou NN,Sofopoulos M,Arnogiannaki N,Stavropoulos-Giokas C,Dinou A,Perez S,Pawelec G,Baxevanis CN,Shipp C

    更新日期:2017-01-01 00:00:00

  • Body mass index, age at breast cancer diagnosis, and breast cancer subtype: a cross-sectional study.

    abstract:PURPOSE:Evidence suggests that premenopausal obesity decreases and postmenopausal obesity increases breast cancer risk. Because it is not well known whether this is subtype dependent, we studied the association between body mass index (BMI) and age at breast cancer diagnosis, or the probability of being diagnosed with ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-017-4579-8

    authors: Brouckaert O,Van Asten K,Laenen A,Soubry A,Smeets A,Nevelstreen I,Vergote I,Wildiers H,Paridaens R,Van Limbergen E,Weltens C,Moerman P,Floris G,Neven P,Multidisciplinary breast centre Leuven.

    更新日期:2018-02-01 00:00:00

  • A scoping review characterizing "Choosing Wisely®" recommendations for breast cancer management.

    abstract:PURPOSE:Choosing Wisely (CW)® was created by the American Board of Internal Medicine (ABIM) to promote patient-physician conversations about unnecessary medical interventions. Similarly, other countries created their own panels of experts called "CW® campaigns" which review recommendations submitted by that country's o...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,评审

    doi:10.1007/s10549-020-06009-2

    authors: Shah H,Surujballi J,Awan AA,Hutton B,Arnaout A,Shorr R,Vandermeer L,Alzahrani MJ,Clemons M

    更新日期:2020-11-06 00:00:00

  • Inhibition of cell proliferation by 17beta-estradiol and heregulin beta1 in estrogen receptor negative human breast carcinoma cell lines.

    abstract::Heregulin (HRG) and 17beta-estradiol (E2) interactions that modulate growth of breast cancer cell lines have recently been demonstrated. We examined the ability of heregulin beta1 (HRGbeta1) and 17beta-estradiol to modulate the biological behavior of estrogen receptor (ER) negative human breast cancer cell lines (AU-5...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1023/a:1006035603635

    authors: Yoo JY,Lessor T,Hamburger AW

    更新日期:1998-09-01 00:00:00

  • A phase II, randomized, multicenter study evaluating the combination of lapatinib and vinorelbine in women with ErbB2 overexpressing metastatic breast cancer.

    abstract::Lapatinib is approved in combination with capecitabine for treatment of patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC) who have progressed on prior trastuzumab in the metastatic setting. Vinorelbine is an important chemotherapy option for MBC. We evaluated efficac...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1007/s10549-013-2828-z

    authors: Janni W,Sarosiek T,Karaszewska B,Pikiel J,Staroslawska E,Potemski P,Salat C,Brain E,Caglevic C,Briggs K,Desilvio M,Marini L,Papadimitriou C

    更新日期:2014-02-01 00:00:00

  • Potentiation of cytotoxic therapies by TNP-470 and minocycline in mice bearing EMT-6 mammary carcinoma.

    abstract::The ability of the antiangiogenic agents TNP-470 and minocycline, singly or in combination, to potentiate the antitumor effects of several cytotoxic therapies was assessed in the murine EMT-6 mammary carcinoma as well as in two drug resistant sublines of that tumor designated EMT-6/CTX and EMT-6/CDDP. The antiangiogen...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/BF00666043

    authors: Teicher BA,Holden SA,Dupuis NP,Kakeji Y,Ikebe M,Emi Y,Goff D

    更新日期:1995-01-01 00:00:00

  • Quality of life in women with metastatic breast cancer during 9 months after randomization in the TEX trial (epirubicin and paclitaxel w/o capecitabine).

    abstract::The aim of this study was to compare the effects on health-related quality of life (HRQOL) of two treatment regimens in the TEX trial during 9 month from random assignment, with emphasis on the 2- and 9-months assessments. A total of 287 patients were randomized to treatment in 3-week cycles with either epirubicin plu...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1007/s10549-010-1084-8

    authors: Svensson H,Einbeigi Z,Johansson H,Hatschek T,Brandberg Y

    更新日期:2010-10-01 00:00:00